Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @DDNewsOnline
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DDNewsOnline
-
.
@aimmune acquires license to#FoodAllergy lead AIMab7195 from#Xencor for $10M upfront + ~$385M milestones Will advance lead to clinical trials w/ help of add’l $200M equity investment from@NestleHealthUS https://www.aimmune.com/pipeline/our-focus/ …#immunotherapy#allergy@CanaleComm@W2OGrouppic.twitter.com/RGTkcm6CfJ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#XChemRx to apply its DNA-encoded library platform to#allergy targets identified by@ALK_net To jointly advance leads, combining X-Chem’s#MedChem expertise w/ ALK’s pre- & clinical expertise http://www.x-chemrx.com/our-science/#immunologypic.twitter.com/RQ1gd75nMd
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@PredictiveOnc’s#TumorGenesis selects@USBiological to manufacture/distribute#OvarianCancer-specific#CellCulture media#Formulation has led to ID of 25 distinct ovarian#tumor cell types;#media available Q1 2020 http://predictive-oncology.com/tumorgenesis/#oncology@Skyline_Medical@NNWMediapic.twitter.com/P6v8aHaWUo
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#LumosDiagnostics closes $15M#SeriesA#financing w/@planetinnovate to advance#FebriDx & launch#clinicaltrials POC#diagnostics provides fingerstick ID of acute#respiratory#infections, IDing#viral vs#bacterial https://www.febridx.com/#workflow#infectiousdisease#pulmonologypic.twitter.com/YkBBdW6azk
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@MaaT_Pharma closes $18M#SeriesB#financing to advance#microbiomic pipeline, expand into#oncology To complete Ph2#clinicaltrials of MaaT013 vs steroid-refractory, GI-predominant#GVHD following#HSCT https://www.maatpharma.com/pipeline/#microbiota#cancers#stemcells@TrophicCommspic.twitter.com/hKAcv5rz0D
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
To accelerate
#protein#biomarker quantitation,@biotechne launches#Quantikine#QuicKit#ELISAs Initial 10#immunoassays using@RnDSystems#antibodies focused on key#immunology targets https://www.rndsystems.com/products/elisas#proteomics#diagnostics#screeningpic.twitter.com/cPSWFvlkIn
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@Pro_SHIME &@CosmosID launch#microbiomics innovation challenge, closing March 31, 2020 Winning approach investigated w/#SHIME GI#simulator &#sequencing analysis for impact on gut#microbiota https://www.cosmosid.com/innovationchallenge …#microbes#genomics#NGS@ResearchUGentpic.twitter.com/BKMymoSWda
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#CODA#Biotherapeutics acquires#Attenua + clinical-stage assets vs#neuropathic#pain, focal#epilepsy & other#neurological conditions To advance leads using#GeneTherapy-mediated#chemogenetic platform https://www.codabiotherapeutics.com/platform#neurosciences#IonChannelspic.twitter.com/BOyAb5VRbC
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#CytoSorb helps reverse#cytokine release syndrome induced by#CAR_Tcell#immunotherapy Blood purification tech used w/ continuous renal replacement therapy &#tocilizumab http://doi.org/10.1097/CCE.0000000000000071 …#cancers#pediatrics#hematology#immunooncologypic.twitter.com/m4pzQpnZix
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@NaverisDx#NavDx effective at detecting#HPV-related head-&-neck#cancers recurrence#LiquidBiopsy IDed#tumor-modified viral DNA w/ 100% sensitivity, 100% NPV & 94% PPV; 3.9-mos median lead time vs#imaging https://doi.org/10.1200/JCO.19.02444 …#diagnostics#oncologypic.twitter.com/OEw5RlKN72
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@Merck to spin-off#WomensHealth &#Biosimilars into unnamed company to achieve $1.5B in operating efficiencies by 2024 NewCo also to snag legacy brands in#dermatology,#pain,#respiratory & some#cardiovascular markets https://merck.unleashinggrowthpotential.com/#pharma#biopharmapic.twitter.com/pgnM0xVqqA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Targeting
#ReproductiveHealth,@thermofisher intros@iontorrent#CarrierSeq ECS kit w/ 420-gene#AmpliSeq panel Kit detects >28K non-benign#ClinVar variants for use in pre- & post-natal,#IVF &#newborn#screening http://www.thermofisher.com/carrierseq#NGS#sequencing@ThermoFisherPRpic.twitter.com/F16vYXvWLO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Researchers compare
#miRNA profiling methods on synthetic & biological#biofluids Find small#RNAseq most accurate, sensitive & specific; HTG#EdgeSeq most reproducible w/ least detection bias https://www.sciencedirect.com/science/article/pii/S2211124719315694 …#NGS#sequencing#biomarkers#openaccess@UCSFMedicinepic.twitter.com/7DM2QWrrH8
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@inositec & collabs screen#library of myo-IP6 derivatives for strong inhibitor of#vascular#calcification In-vitro & rodent#models demo efficacy of INS-3001 w/out#toxicity assoc w/ serum calcium#chelation http://doi.org/10.1038/s41467-019-14091-4 …#cardiology#cardiovascular#openaccesspic.twitter.com/zc4f1kqJYe
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
British
#oncology researchers get entrepreneurial boost as@StartCodon joins@CR_UK initiative Seek to facilitate business dev’t by educating scientists on company formation,#operations &#financing https://startcodon.co/cruk#pharma#biotech#biopharma#diagnostics@ZymeCommspic.twitter.com/FPoaOW3Tn9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BMS &
@BioMotiv launch#Anteros#Pharmaceuticals to target#fibrotic &#inflammatory disease W/@Yale collabs,#BioMotiv to assume R&D duties while@bmsnews contributes IP, data & reagents https://www.biomotiv.com/our-approach#biotech@macbiocompic.twitter.com/yiMFJCJXyU
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#PlexPharma awarded $600K@NIHsbir grant via@NIAIDFunding to fine-tune#antivirals vs#Dengue,#WestNile &#Zika Optimizing broad-spectrum inhibition of#flavivirus#protease NS3, central to viral#replication https://www.plexpharma.com/#infectiousdisease#GlobalHealthpic.twitter.com/oksORR95eo
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Tramadol active metabolite#desmetramadol effective in#pain relief, doesn’t trigger#opioid-induced#respiratory pathways#Syntrix developing#metabolite to improve efficacy while ↓ side effects https://doi.org/10.3389/fphar.2019.01680 …#neurosciences#openaccess#pharmacology@FrontPharmacolpic.twitter.com/dIR2picn1P
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Würzburg University Hospital to test
@skylinedx#MMprofiler (SKY92) vs multiple#myeloma in real-world setting Study reliability of 92#oncogene panel vs internal clinical standards over 5 years https://www.mmprofiler.com/home#oncology#diagnostics#genomics@Uni_WUEpic.twitter.com/2VY7zda1n4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@MassGeneralNews’ & Steven Grinspoon to help@Theratech_#clinicaltrials of#tesamorelin vs#NAFLD &#NASH in subjects w/#HIV Recently published study showed synthetic#GHRH ↓ liver fat &#fibrosis progression https://www.theratech.com/en/products/egrifta-f8-nash-hiv/#content …#LiverDisease#FattyLiverpic.twitter.com/vmHpY58iF7
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.